Cocrystal Pharma Inc (COCP)

Several events have impacted Cocrystal Pharma's stock price in the past six months. In August 2025, the company presented favorable safety and tolerability Phase 1 data for CDI-988 at the 2025 Military Health System Research Symposium (MHSRS). In September 2025, Cocrystal Pharma received a "Study May Proceed Letter" from the FDA for a Phase 1b challenge study in the U.S. for CDI-988 and raised $4.7 million in gross proceeds. In October 2025, the company completed an at-the-market financing. In November 2025, Cocrystal Pharma reported its financial results for Q3 2025, expects to begin enrolling participants in the norovirus challenge study for CDI-988 in Q1 2026, and received an SBIR award from the NIH. As of February 4, 2026, the overall moving average trend for COCP stock leans bearish, with the stock price decreasing by 0.9% since January 1, 2026.

The demand for some of Cocrystal Pharma's products is likely to exhibit seasonality. Influenza outbreaks occur predominantly during the winter months, suggesting higher demand for influenza treatments like CC-42344 during these periods. Norovirus, while not explicitly stated as seasonal, could lead to periods of increased outbreaks and thus higher demand for treatments like CDI-988.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antiviral therapeutics, operating within the biotechnology sector, specifically the medical - biomedical and genetics industry. The company utilizes a unique structure-based drug discovery technology platform and leverages Nobel Prize-winning expertise to create antiviral drugs. The company's major product pipeline candidates target the replication process of various viruses, including influenza viruses, coronaviruses, noroviruses, and hepatitis C viruses (HCV). CC-42344 is a novel PB2 inhibitor in Phase 2a clinical trials for the treatment of pandemic and seasonal influenza A, with an inhaled version being developed for prophylactic treatment. CDI-988 is an oral broad-spectrum protease inhibitor being developed as a potential prevention and treatment for norovirus and coronavirus infections, demonstrating superior broad-spectrum antiviral activity. CC-31244 is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.

Cocrystal Pharma, Inc. is headquartered in Bothell, Washington, USA. The company's clinical development activities extend internationally, with a Phase 2a human challenge study for CC-42344 being conducted in the United Kingdom. Additionally, a Phase 1b challenge study for CDI-988 is planned to begin in the U.S.

Based on the available information, Cocrystal Pharma's brand reputation in the past year appears to be generally positive or neutral, primarily driven by its ongoing clinical progress and scientific advancements. There were no significant negative events, controversies, or product recalls reported that would adversely impact its reputation. Analyst ratings for Cocrystal Pharma are largely positive, with a consensus rating of "Strong Buy" or "Hold" from various firms. The company has actively communicated its progress in clinical trials and financial updates, which contributes to maintaining transparency and investor confidence.

As of September 30, 2025, Cocrystal Pharma, Inc. has 29 institutional owners and shareholders holding a total of 669,970 shares. Major institutional owners include Vanguard Group Inc., Renaissance Technologies Llc, Geode Capital Management, Llc, BlackRock, Inc., Neuberger Berman Group LLC, Jane Street Group, Llc, State Street Corp, and Parallel Advisors, LLC. Specific major individual owners with recent data were not prominently identified in the search results.